Bevacizumab Biosimilar – Anti-VEGF mAb – Research Grade

Description of Bevacizumab Biosimilar - Anti-VEGF mAb - Research Grade

General information about Bevacizumab

Bevacizumab, is classified as a monoclonal antibody and/or anti-angiogenesis drug. It is a comparatively new type of cancer therapy. Antibodies are an essential part of the immune system. The body creates antibodies in response to an antigen entering the body. These antibodies attach themselves to the antigen, to mark it for destruction by the body’s immune system. Bevacizumab allows human body to target specific cells, causing less toxicity to healthy cells. It works by interfering with the process of angiogenesis by targeting and inhibiting human vascular endothelial growth factor (VEGF). VEGF is a cytokine (a small protein released by cells that have specific effects on the behavior of cells) which when it interacts with its receptors in the cell leads to new blood vessel formation or angiogenesis. This product is for research use only.

SDS-PAGE for Bevacizumab Biosimilar - Anti-VEGF mAb

Bevacizumab Biosimilar - Anti-VEGF mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Bevacizumab Biosimilar - Anti-VEGF mAb binds to VEGFA / VEGF165, C-His, recombinant protein in Indirect ELISA

Immobilized VEGFA / VEGF165, C-His, recombinant protein (cat. No. PX-P5977) at 0.5µg/mL (100µL/well) can bind Bevacizumab Biosimilar - Anti-VEGF mAb (cat. No. PX-TA1006) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 97.73M.